Table 2.

Linear regression of association between aortic stiffness and clinical factors with significant associations in italic

	AAD			DAD			PWV
	Beta	95% CI	P value	Beta	95% CI	P value	Beta	95% CI	P value
Age	− 0.063	− 0.080; − 0.046	< 0.0001	− 0.052	− 0.068; 0.036	< 0.0001	0.11	0.064; 0.16	< 0.0001
Male gender	0.13	− 0.47; 0.73	0.69	− 0.18	− 0.73; 0.36	0.50	0.11	− 1.39; 1.61	0.88
Body mass index	0.0042	− 0.051; 0.060	0.88	− 0.030	− 0.080; 0.020	0.24	− 0.30	− 0.17; 0.11	0.67
Duration of diabetes	− 0.037	− 0.090; 0.016	0.17	− 0.040	− 0.090; 0.0050	0.08	0.087	− 0.044; 0.22	0.19
HbA1c	− 0.016	− 0.031; − 0.00073	0.04	− 0.00037	− 0.014; 0.013	0.96	0.027	− 0.010; 0.065	0.15
Median HbA1c since diagnosis	− 0.013	− 0.029; 0.0026	0.10	0.00084	− 0.013; 0.015	0.91	0.019	− 0.020; 0.058	0.33
Maximum HbA1c since diagnosis	− 0.011	− 0.020; − 0.0014	0.02	− 0.0035	− 0.012; 0.0050	0.42	0.0083	− 0.016; 0.032	0.50
Microalbuminuria	− 0.21	− 0.69; 0.26	0.37	− 0.21	− 0.64; 0.22	0.34	0.89	− 0.28; 2.06	0.13
24 h systolic BP	− 0.026	− 0.040; − 0.011	0.001	− 0.020	− 0.034; − 0.0067	0.004	0.040	0.0014; 0.078	0.04
24 h diastolic BP	− 0.0058	− 0.033; 0.021	0.67	− 0.0027	− 0.027; − 0.022	0.83	− 0.0015	− 0.068; 0.065	0.97
Total cholesterol	0.15	− 0.062; 0.36	0.16	0.056	− 0.14; 0.25	0.57	− 0.44	− 0.97; 0.081	0.10
Smoking	0.11	− 0.54; 0.76	0.74	0.098	− 0.49; 0.69	0.74	− 0.59	− 2.20; 1.02	0.47
Metformin	0.27	− 0.47; 1.01	0.47	0.35	− 0.31; 1.02	0.30	0.32	− 2.16; 1.51	0.73
Sulphonylurea	− 0.57	− 1.06; − 0.08	0.02	0.34	− 0.79; 0.11	0.14	1.17	− 0.056; 2.39	0.06
Gliptin	− 0.31	− 1.08; 0.46	0.43	0.14	− 0.57; 0.83	0.70	0.73	− 1.18; 2.64	0.45
Statin	− 0.048	− 0.57; 0.47	0.86	− 0.13	− 0.60; 0.35	0.60	0.38	− 0.91; 1.67	0.56
Aspirin	− 0.61	− 1.23; 0.012	0.06	− 0.51	− 1.08; − 0.51	0.07	1.10	− 0.46; 2.66	0.16

Significant associations in italics

Abbreviations as in Table 1